AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

Listing of Claims

- 1-7. (Canceled):
- 8. (Currently Amended): A method for producing O-glycan $\alpha 2,8$ -sialyltransferase, comprising

in vitro culturing a transformant of isolated host cells transformed with an expression vector comprising either of the following nucleotide sequences:

(±) a nucleotide sequence corresponding to a portion between nucleotide 77 and nucleotide 1270 of a nucleotide sequence shown in SEQ ID NO: 2; and

(2) a nucleotide sequence corresponding to a portion between nucleotide 92 and nucleotide 1285 of a nucleotide sequence shown in SEQ ID NO: 4; and collecting O-glycan α2,8-sialyltransferase from the culture.

- 9-14. (Canceled):
- 15. (Currently Amended): A method for producing a protein comprising an active domain of O-glycan α2,8-sialyltransferase comprising in <u>vitro</u> culturing a transformant of isolated host cells transformed with an expression vector comprising a gene encoding a protein <u>comprising amino acids 26 to 398 of the amino acid sequence</u> shown in SEQ ID NO: 1 aeeerding to elaim 9: and collecting the protein from the culture.

16-30. (Canceled):

31. (New): A method of selectively incorporating sialic acid into O-glycans in a mammal, comprising administering an effective amount of a O-glycan $\alpha 2.8$ -sialyltransferase or a protein comprising an active domain of O-glycan $\alpha 2.8$ -sialyltransferase, wherein the O-glycan $\alpha 2.8$ -sialyltransferase has substrate specificity towards glycoconjugates with a Sia $\alpha 2.3$ (6)Gal structure (Sia represents sialic acid and Gal represents galactose at the terminus thereof), and wherein the O-glycan $\alpha 2.8$ -sialyltransferase has the amino acid sequence shown in SEQ ID NO: 1 or comprises the amino acids 26 to 398 of SEQ ID NO: 1.

32 (New): The method of claim 31, used for the treatment of a hereditary disease caused by a deficiency of sugar chains.

33 (New): The method of claim 31, used to suppress the growth of cancer metastasis.

34 (New): The method of claim 31, used to study an influence of a physiological activity by combining sialic acid with at least one pharmaceutically active ingredient.